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Abstract
Purpose—To evaluate whether there is racial variation in venous umbilical cord blood
concentrations of sex steroid hormones and the insulin-like growth factor (IGF)-axis between
female African-American and white neonates.
Methods—Maternal and birth characteristics and venous umbilical cord blood samples were
collected from 77 African-American and 41 white full-term uncomplicated births at two urban
hospitals in 2004 and 2005. Cord blood was measured for testosterone, dehydroespiandrosterone-
sulfate (DHEAS), estradiol, sex-steroid hormone binding globulin (SHBG) by immunoassay.
IGF-1, IGF-2, and IGF binding protein-3 (IGFBP-3) were measured by ELISA. Crude and
multivariable-adjusted geometric mean concentrations were computed for the hormones.
Results—African-American neonates weighed less at birth (3,228 vs. 3,424 grams, p<0.004)
than whites. Birth weight was positively correlated with IGF-1, IGFBP-3 and the molar ratio of
IGF1 to IGFBP-3, but inversely correlated with the molar ratio of IGF-2 to IGFBP-3. Adjusted
models showed higher testosterone (1.82 vs. 1.47 ng/mL, p=0.006) and the molar ratio of
testosterone to SHBG (0.42 vs. 0.30, p=0.03) in African-American compared to white female
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neonates. IGF-1, IGF-2, and IGFBP-3 were lower in African-American compared to white female
neonates, but only the difference for IGF-2 remained significant (496.5 vs. 539.2 ng/mL, p=0.04).
Conclusion—We provide evidence of racial variation in cord blood testosterone and
testosterone to SHBG in African-American compared to white female neonates, and higher IGF-2
in white compared to African-American female neonates. Findings suggest plausible explanations
for a prenatal influence on subsequent breast cancer risk and mortality. Further work is needed to
confirm these observations.
Keywords
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Introduction
Breast cancer is the leading cause of cancer death among US women. Although the
incidence is higher for white women > 40 years of age, recent US trends reveal a crossover
in age-adjusted incidence with higher rates in African-American < 40 years of age [1, 2].
Overall, black women are far more likely to be diagnosed with aggressive breast cancer at a
later-stage, less likely to receive stage-appropriate treatment, and have lower stage-for-stage
survival rates [3, 4]. A number of biological, socioeconomic and lifestyle factors that are
known to be related to increased risk might also be contributing to this differential in
prognosis seen in black as compared to white women. Among the endogenous factors
associated with breast cancer risk are circulating levels of sex steroid hormones and the
insulin-like growth factor (IGF) axis. We hypothesize that perturbations in endogenous
hormones and growth factors in utero may also account for a small part of the racial
disparity in breast cancer incidence and mortality.
Estrogens and androgens have been established as mitogens in normal breast as well as
breast cancer cells, and levels of these hormones have been shown to play a role in
determining breast cancer risk [5, 6]. When examining racial differences, several
epidemiologic studies have shown a direct association between elevated levels of estradiol,
estrone and low SHBG with breast cancer risk, particularly in African American women
compared to whites. A study in 420 pregnant women found African Americans to have
higher concentrations in androstenedione, testosterone, and progesterone than Caucasian or
Hispanic women [7], which may influence risk of adult cancer in their offspring.
Additionally, insulin-like growth factors (IGF)-1 and IGF-2 have been implicated in breast
tumorigenesis because of their ability to stimulate mitogenesis and their key role in
mammary gland cell proliferation and survival [8, 9]. Investigations of racial/ethnic
differences reveal that African-American women have elevated levels of total IGF-1 and
free IGF-1 relative to whites [10–12], with similar trends being observed among both
prepubertal and pubertal African-American girls [13] [14].
Over 20 years ago Trichopoulos [15] postulated that exposure to elevated endogenous
hormones during pregnancy might contribute to subsequent breast cancer risk in adulthood.
During pregnancy, sex steroid hormones are greatly elevated and play an essential role in
normal development of the breast in the mother, whereas the IGF-axis stimulates cell
division and differentiation and regulates fetal and weight gain (12, 13). These hormones
and growth factors have been estimated to be at least 10 times higher in pregnant than non-
pregnant women, and they steadily increase with advancing gestational age [15]. Although
these hormones are needed for normal growth and development, they also play an important
role in breast carcinogenesis. Epidemiologic studies suggest that in utero hormonal
perturbations can impact perinatal factors, such as birth weight and length. As a result,
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perinatal measures are used as surrogate indicators of intrauterine exposure. Several meta-
analyses provide evidence for an association between increased birth weight, birth length,
and higher maternal and paternal age with subsequent breast cancer risk in adulthood [16–
18]. High birth weight appears to be associated specifically with premenopausal breast
cancer risk. In the Swedish Twin Registry, for example, birth weight > 3000 g was
associated with increased risk of breast cancer diagnosis at or before 50 years (HR, 1.57;
95% CI, 1.03–2.42) [19]. Higher birth weights are, in turn, associated with elevated estrogen
and IGF-1 concentrations in umbilical cord blood [20–23]. Despite this evidence supporting
an association between exposure to sex steroid hormones and IGF-axis hormones in utero
and breast cancer risk in adulthood, few studies have explored potential contributions of
these factors to the observed racial disparities in breast cancer risk.
We investigated differences in venous umbilical cord blood concentrations of sex steroid
hormones and components of the IGF-axis between African-American and white female
neonates. This study provides the opportunity to fill the gap in knowledge about racial
variations in the hormonal and growth factor in utero environment, taking into account
racial differences in maternal and birth characteristics. Further, we considered whether racial
variation in these factors may be a plausible explanation for notably higher US breast cancer
incidence in premenopausal and higher mortality in both pre-and postmenopausal African-
American women.
Materials and Methods
Study population
Neonates were identified for a pilot study called the Hormones in Umbilical Cord Blood
Study (HUB Study), which was a project that was part of the National Cancer Institute
partnership awarded to the Howard University Cancer Center and the Sidney Kimmel
Comprehensive Cancer Center at Johns Hopkins. The aim of the NCI partnership grant was
to enhance the research, training, outreach, and education missions of both institutions. The
Institutional Review Board of Prince George’s Hospital Center and the Johns Hopkins
Bloomberg School of Public Health approved both studies.
The delivery room nurses were asked to anonymously collect demographic data and venous
umbilical cord samples for neonates delivered at the Prince George’s Hospital Center in
Cheverly, MD (Hospital 1) and the Johns Hopkins Hospital in Baltimore, MD (Hospital 2).
Inclusion criteria for neonates were full term birth defined as between the 38th and 42nd
gestational week, birth weight between 2500 and 4000 g, no major birth defects, and
singleton birth. For the mother, the exclusion criteria included pregnancy complications
(e.g., pre-eclampsia, toxemia, and hypertension), gestational diabetes, diabetes mellitus,
thyroid disease, use of hormonal medications during pregnancy, and known growth hormone
deficiency. For the neonates, both the mother and father were required to be of the same
race, either African-American or white.
Between February 2004 and June 2005, demographic data and cord blood samples were
collected for eligible births at the two hospitals by the delivery room nurses. Using a
standardized form, the nurses collected the following information: month and time
(quadrant) of day of the birth, birth weight, placental weight, mother/child’s race, and
mother’s age, parity (number of live births), and gravidity (number of pregnancies). A total
of 15 mL of blood from the umbilical cord vein was drawn into two tubes containing sodium
EDTA and immediately stored in a refrigerator. Within approximately 12 hours and at room
temperature, the samples were centrifuged for 15 minutes at 2400 rpm. Plasma, buffy coat,
and red cells were aliquoted into cryovials and stored at −70°C.
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We collected cord blood specimens from 127 female births at the two hospitals. Of the total
sample, 5 were excluded because they did not meet the birth weight eligibility criterion and
4 were excluded because they were not of adequate quality or did not meet other eligibility
criteria. Thus, the final sample size was 118, of which 41 were white and 77 African-
American. Before shipping and testing, all samples were randomly arrayed by hospital and
race and blinded quality control cord blood samples were included to assess assay reliability.
An overnight courier was used to ship plasma samples on dry ice to the two collaborating
laboratories.
Exposure assessment
Sex steroid hormones, testosterone, estradiol, dehydroespiandrosterone-sulfate (DHEAS)
and SHBG were measured by competitive immunoassay (1010 Elecsys autoanalyzer, Roche
Diagnostics, Indianapolis, IN) in the laboratory of Nader Rifai, PhD, (Children’s Hospital,
Boston, MA). IGF-1, IGF-2 and IGFBP-3 were measured by ELISA (Diagnostics Systems
Laboratory) in the laboratory of Michael N. Pollak, MD (Jewish General Hospital and
McGill University, Montreal, Canada). The laboratory technicians were blinded to race and
hospital. The lowest detection limits of the assays were: testosterone 0.02 ng/mL, estradiol 5
pg/mL, DHEAS, and SHBG 0.35 nmol/L. IGF-1, 0.03 ng/mL; IGF-2, 24 ng/mL; and
IGFBP-3, 0.04 ng/mL. The quality control specimens had the following coefficients of
variation: testosterone 6.9%; estradiol 15.7%, SHBG 8.3%; DHEAS; IGF-1, 12.3%; IGF-2,
6.2%; and IGFBP-3, 6.8%.
Statistical analysis
Several hormones were not normally distributed so we calculated the geometric mean for all
plasma concentrations of sex steroid hormones, SHBG, and IGF-axis factors in the cord
blood of the African-American and white female neonates. Differences in sex steroid
hormones and growth factors were tested by race using the t-test. We also present the
geometric means for all sex steroid hormones and growth factors adjusted for birth weight,
placental weight, mother’s age and parity, and quadrant of day of birth, since the distribution
of possible determinants of cord blood hormone levels may differ by race and thereby
confound the findings. We estimated differences in geometric means using generalized
linear models.
We also examined whether the molar ratio of testosterone and estradiol to SHBG and the
molar ratio of IGF-1 and IGF-2 to IGFBP-3 varied by race crudely and after adjusting for
the other possible determinants of cord blood concentrations. This analysis was important
since binding proteins modify the bioavailability of steroid and peptide hormones. The
molar ratios provide an estimate of the free or bioavailable amount of hormone or IGF in
circulation. SHBG is the major carrier of both testosterone and estradiol in circulation and
when bound to SHBG, these hormones are not available for androgenic and estrogenic
signaling. Similarly, IGFBP-3 is the major carrier of IGF-1 and IGF-2 in circulation, and
when bound IGF-1 and -2 are not available to signal. We did not measure free levels of
these analytes. All analyses were conducted using SAS v. 9 (SAS Institute, Cary, NC).
Results
Table 1 shows the birth characteristics of 118 mothers and their female babies by race.
Mothers of African-American neonates were significantly younger than mothers of white
neonates (24.1 vs. 28.2 yr, p<0.0005) and were more likely to have ≥3 live births. Also,
African American babies weighed less at birth (3,228 vs. 3,424 grams, p<0.004) and had
lighter placental weights (659 vs. 675 g) than white babies, although the latter was not
statistically significant. Since African Americans were born at two different hospitals, we
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compared maternal and birth-related characteristics between the two hospitals. African
Americans births from hospital 2 compared to hospital 1 had heavier placental weight (691
vs. 613 g, p<0.03) and their mothers were more likely to be nulliparous. The time of day of
birth varied within both hospitals. Since the patterns were similar for African-American
births at hospitals 1 and 2 when compared to white births, we combined all African-
American births into one category, which is included in subsequent analyses.
Spearman correlation coefficients were calculated for birth characteristics with cord blood
hormone and IGF-axis concentrations taking into account race (Table 2). Birth weight was
statistically significantly correlated in a positive direction with concentrations of IGF-1,
IGFBP-3 and the molar ratio of IGF1 to IGFBP-3, but inversely correlated with the molar
ratio of IGF-2 to IGFBP-3. In addition, we observed a statistically significant inverse
correlation between parity and concentrations of testosterone, estradiol, and a near
significant association with the molar ratio of estradiol to SHBG. A statistically significant
positive correlation was observed between placental weight and IGFBP-3 concentrations.
Median and interquartile ranges for cord blood sex steroid hormone and growth factor
concentrations by race are shown in Table 3. There were no major differences in cord blood
concentrations between African-American and white neonates with respect to the
distributions of sex steroid hormones, SHBG and the molar ratios of testosterone and
estradiol to SHBG. However, African Americans had significantly lower median
concentrations of IGF-1, IGF-2 and IGFBP3 than whites, although no racial differences
were found for the molar ratios of IGF-1 and IGF-2 to IGFBP-3.
Crude and multivariable-adjusted geometric mean hormone and growth factor
concentrations and 95% confidence intervals by race are shown in Table 4. In our
examination of crude geometric means (model A), we did not observe statistically
significant differences in cord blood concentrations of testosterone, DHEAS, estradiol and
SHBG by race. Although not significant, the cord blood levels were slightly higher among
white neonates compared to African Americans, with the exception of testosterone. After
adjusting for birth weight, placental weight, mother’s age, parity and time of day of birth
(model B), the concentration of testosterone was significantly higher in African-American
neonates than in whites (1.79 vs. 1.49 ng/mL, p=0.02). The mutually adjusted model (model
C) as opposed to the crude (model A) or the adjusted model (model B) revealed significantly
stronger racial differences for testosterone concentration between African Americans and
whites (1.82 vs. 1.47 ng/mL, p=0.006). The difference between African-American and white
female neonates with respect to the crude geometric mean molar ratios of testosterone to
SHBG (model A) was near significance (p=0.06), but after multivariable adjustment (model
B), this molar ratio was statistically significantly higher in African-American neonates
compared with whites (0.42 vs. 0.30, p=0.03).
In contrast to sex steroid hormones, cord blood concentrations of the growth factors differed
significantly by race (Table 4). In the crude model (model A), African-American neonates
had statistically significantly lower cord blood concentrations for IGF-1, IGF-2, and
IGFBP-3 when compared to white neonates. Although not statistically significant, the molar
ratio of IGF-1 to IGFBP-3 was lower in African-American than in white neonates (0.19 vs.
0.22, p=0.08). After multivariable adjustment (model B), the concentrations were still
slightly lower in African Americans, but only the difference for IGF-2 remained
significantly lower in African American neonates than in whites (496.5 vs. 539.2 ng/mL,
p=0.04). In this model, there were no statistically significant racial differences in the molar
ratios for IGF-1 and IGF-2 to IGFBP-3.
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Discussion
The purpose of this study was to evaluate whether there is racial variation in venous
umbilical cord blood concentrations of sex steroid hormones and the insulin-like growth
factor (IGF)-axis between female African-American and white neonates. Our analyses were
adjusted for birth weight, placental weight, mother’s age, mother’s parity, and time of day of
birth. We did not find racial differences in cord blood concentrations of estradiol, DHEAS,
SHBG and the molar ratio of estradiol to SHBG. However, we did observe both higher
testosterone levels and the molar ratio of testosterone to SHBG, an indicator of bioavailable
testosterone, in the cord blood of African-American compared to white female neonates.
Cord blood concentrations of IGF-1, IGF-2, and IGFBP-3 were significantly lower in
African-American than white female neonates in the crude model, but only IGF-2 remained
significant in the multivariable model. In both the crude and multivariate models, the molar
ratios for IGF-1 and IGF-2 to IGFBP-3 did not differ by race.
Sex steroid hormones
Two studies examined racial/ethnic differences in umbilical cord blood sex steroid
hormones in female neonates [21, 24]. One found higher non significant estradiol levels in
Asian than Caucasian and Hispanic neonates [21]. The other study did not find ethnic/racial
differences between European, Maori, South Asian, and Pacific Islands [24]. These findings
are consistent with studies that combined female and male neonates [22, 25]. After
controlling for factors related to pregnancy, Troisi et al. [22] did not find significant
differences in cord blood estradiol levels between Chinese and white neonates. Contrary to
these findings, Lagiou et al. [26] found significantly higher levels of cord blood estradiol
and SHBG in Chinese compared to whites in a combined sample of female and male
neonates. Another study found non-significant differences in cord blood estradiol and
DHEAS concentrations between African American and white female and male neonates
[25]. Similar to that study, we did not find significant differences in cord blood estradiol,
DHEAS and SHBG concentrations between African American and white neonates, although
the levels tended to be lower in our African-American neonates. It has been suggested that
lower SHBG may be inversely correlated with measures of hematopoietic stem cell
potential, which may increase risk for breast cancer [27]. Understanding the relationship
between low SHBG concentrations and breast cancer risk in our sample needs further
investigation. We did not find correlations between birth weight and cord levels of estradiol,
DHEAS or SHBG, which is consistent with other studies [25, 28]; however, estradiol was
inversely correlated with parity. Only one study found a positive correlation between cord
blood DHEAS levels with birth weight in normal, singleton pregnancies [25]. Overall, our
lack of an association for racial differences in estradiol, DHEAS and SHBG appears to
corroborate the findings in other studies [21, 22, 24, 25].
Few studies found significantly elevated testosterone levels in African American women
during the early weeks of gestation when compared to whites [25, 29]. When measuring
cord blood testosterone concentrations, studies found higher levels for Chinese compared to
white neonates [22, 26]; whereas others did not find significant differences [24, 25]. We
found significantly higher testosterone levels in African American compared to white
neonates. Elevated intrauterine testosterone concentrations are associated with restricted
fetal growth in both animal and human studies [30–32] and is believed to reduce the nutrient
supply to the placenta and/or modify placental function, thus restricting growth [30]. In our
study, African American female neonates, who had higher cord blood testosterone levels
than whites, also had smaller birth weights compared to whites. However, we found no
correlation between testosterone with birth weight for both African-American and white
neonates. This finding is consistent with other studies [25, 33]. Whether racial differences in
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adult premenopausal breast cancer is associated with in utero perturbations to testosterone
levels remains to be determined.
IGF-Axis
Few studies have examined racial variation in umbilical cord blood levels of IGF-1, IGF-2
and IGFBP-3 and the literature is somewhat mixed. Racial differences in IGF-1 cord blood
concentrations were seen in US whites compared with Chinese neonates [26, 34]; whereas
Chinese neonates had higher levels of IGF-2 compared to white neonates. However, others
did not find differences in cord IGF-1 concentrations among other racial/ethnic groups in
female neonates [21, 24] and a sample of combined female and male neonates [22]. We
observed differences in growth factor concentrations in cord blood between African-
American and white female neonates. Although not statistically significant, African
American neonates had lower concentrations of IGF-1 and lower birth weights than did the
white neonates.
The literature suggests that cord blood IGF-1 concentrations are positively correlated with
birth weight and length among taller US white women [34]. Specifically, higher cord IGF-1
and IGFBP-3 concentrations have been correlated with higher birth weight, birth length,
head circumference and other anthropometry measures [21, 35–37] whereas lower IGF-1
and IGFBP-3 concentrations are associated with preterm or small for gestational age
neonates [37, 38]. The relationship between IGF-1 and birth weight is important since they
both have been associated with risk of breast cancer [16–18]. In our study, African
American neonates had lower IGF-1 concentrations and lower birth weights, which is
contrary to the hypothesis that elevated intrauterine IGF-1 concentrations increases risk for
breast cancer later in life.
We found significantly lower cord blood concentrations of IGF-2 in African American
neonates compared to whites. Studies suggest that IGF-2 is important for fetal growth and
development [39, 40] and concentrations are lower in preterm rather than full term neonates
[41, 42]. One study reported higher circulating levels of IGF-2 with birth weight and length
among Chinese compared to white neonates [34]. Others found a weak relationship to birth
size/weight [43], and the molar ratio of IGF-2 to soluble IGF-2/mannose-6-phosphate
receptor with birth weight [44]. Our finding of lower mean IGF-2 concentrations among
African American neonates does not support the hypothesis that elevated levels may mediate
the associated of prenatal factors with subsequent breast cancer in this population, but
instead suggest a potential risk among white neonates with higher IGF-2 expression. Similar
to our results for African American neonates, a low ratio of IGF-2:IGFBP3 was found in
Afro-Caribbean women than whites, after adjustment for mean body mass index [10].
We compared our patterns of cord blood hormone and growth factors in females to a
separate investigation that examined male neonates using samples from the HUB study [45].
We found that the patterns of the racial difference were similar in female and males. The
bioavailable testosterone in cord blood was higher in both female and male African-
Americans than in whites and that IGF axis components were lower in both female and male
African-Americans than whites.
In our study the African American female neonates were smaller and had lower placental
weights when compared to the white neonates, which has been documented in the US
population. Fetal growth is regulated by hormones and growth factors as well as the
nutritional environment. During fetal development there is programming of several
biological systems, which can be negatively impacted by intrauterine growth restriction [46]
and influence disease risk later in life. In addition to prenatal or in utero growth restriction,
postnatal birth weight might also increase breast cancer risk. For example, small for
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gestational age infants who experience accelerated growth in childhood develop insulin
resistance as a result of rapid weight gain [47]. Insulin resistance and/or hyperinsulinemia
are considered risk factors not only for diabetes, but also breast cancer [48–50], as
hyperinsulinemia can promote breast cancer cell proliferation. Moreover, adults and children
who were born small for gestational age experience metabolic abnormalities (e.g. obesity,
insulin resistance, hypertension and dyslipidemia) similar to metabolic syndrome. A recent
study found that metabolic syndrome was more prevalent in triple-negative breast cancer
than non-triple negative patients [51]. Taken together, the intrauterine environment plays a
critical role in fetal growth and development, and thus, can set the stage for increased breast
cancer risk later in life. Studies are needed to fully elucidate the biological mechanism (s)
and/or epigenetic changes that occur in utero as well as the role of catch up growth in low
birth weight babies and subsequent breast cancer.
Strengths and Limitations
There are a number of strengths such as the exclusion of neonates who were very small (<
2500 g) or large (> 4000 g) and were born to mothers who experienced pregnancy
complications such as preeclampsia or gestations diabetes. Also, we included only female
neonates because of our interest in risk for adulthood breast cancer. At the time of birth,
blood was drawn from the umbilical cord vein, which represents blood flow from the
placenta to the baby. Umbilical cord blood is believed to be a good indicator of fetal
exposure to hormonal and growth factor systems because it reflects three sources: fetal
production, placental production, and maternal production.
We presented crude and adjusted hormone and growth factor concentrations, both of which
may provide valuable information on racial differences in cord blood levels. The differing
plasma levels represent the actual levels experienced by the fetus at the end of pregnancy.
Thus, variation in these actual levels might be an explanation for the racial variation in
breast cancer and mortality later in life.
There are several possible limitations to our study. We did not collect information on
maternal lifestyle factors such as diet, physical activity and smoking, which may affect
circulating concentrations of sex steroid hormones and growth factors in umbilical cord
blood. Also, we could not determine if the stress of labor and delivery affected hormone
levels for both fetal and maternal blood samples. Additionally, the sex steroid hormone
concentrations measured in the HUB study were in the lower range compared to previous
studies [25, 26, 52]. Our growth factor concentrations were in the higher range compared to
another study [21], but similar to results reported by Lagiou et al. [26]. The differences in
the cord blood concentrations among studies might be reflective of differences among the
study populations (e.g. racial/ethnicity, BMI), the collection of venous versus arterial cord
blood, differences in blood collection procedures or in assay methods and variability.
Another potential limitation is that we collected samples from two different hospitals.
Reflecting the demographics of their catchment areas, Hospital 1 included African-
American births whereas hospital 2 included both African-American and white births.
Because the maternal and birth characteristics did not differ markedly between the African-
American babies born at the two hospitals, we combined data for the African-American
births in the final analyses.
Conclusion
In conclusion, we observed racial differences in cord blood concentrations of sex steroid
hormones and the IGF axis between African-African and white female neonates. Significant
racial differences were found for circulating levels of testosterone and the molar ratio for
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testosterone to SHBG, after controlling for maternal and birth characteristics. The higher
bioavailable testosterone concentrations in African American female neonates compared
with whites is consistent with what has been reported in the literature and may mediate the
association of prenatal factors with subsequent breast cancer risk. Contrary to elevated
testosterone concentrations, African American female neonates exhibited significantly lower
concentrations of IGF-2, which is essential for early fetal growth and has been shown to be a
marker for tumor growth and survival. Research is needed to identify those factors that
influence perturbations in circulating hormones and growth factors (e.g. mother’s
anthropometric measurements and lifestyle factors) in the intrauterine environment and
determine what role, if any, they contribute to breast cancer racial disparities. Understanding
these mechanisms can help to advance efforts in breast cancer prevention and control.
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Table 2
Spearman correlation coefficients* (P value) between maternal and birth characteristics and sex steroid
hormone and growth factor concentrations in venous umbilical cord blood, females, HUB Study 2004 to 2005
Birth weight Placental weight Parity Mother's age
Testosterone 0.12 (0.22) 0.08 (0.41) −0.28 (0.003) 0.04 (0.69)
DHEAS 0.002 (0.98) −0.05 (0.58) −0.07 (0.45) 0.01 (0.90
Estradiol 0.05 (0.60) −0.04 (0.65) −0.29 (0.002) −0.12 (0.22)
SHBG −0.11 (0.27) −0.07 (0.47) −0.03 (0.80) −0.01 (0.96)
IGF-1 0.34 (0.0003) 0.14 (0.14) 0.09 (0.34) 0.13 (0.16)
IGF-2 0.07 (0.45) 0.08 (0.42) 0.09 (0.34) 0.08 (0.40
IGFBP-3 0.29 (0.002) 0.2 (0.03) −0.03 (0.79) 0.14 (0.14)
Molar ratios of
   Testosterone/SHBG (×103) 0.1 (0.28) 0.05 (0.64) −0.13 (0.19) −0.009 (92)
   Estradiol/SHBG 0.02 (0.84) −0.03 (0.72) −0.18 (0.06) −0.1 (0.28)
   IGF-1/IGFBP-3 0.31 (0.001) 0.1 (0.29) 0.13 (0.19) 0.08 (0.38)
   IGF-2/IGFBP-3 −0.26 (0.005) −0.16 (0.1) 0.07 (0.47) −0.11 (0.24)
   (IGF-1+IGF-2)/IGFBP-3 −0.12 (0.21) −0.11 (0.25) 0.14 (0.14) −0.05 (0.63)
*
Adjustd for race
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Table 3
Distribution of sex steroid hormone and growth factor concentrations in venous umbilical cord blood by race,
females, HUB Study 2004 to 2005
AA (n=77) W (n=41)
Median Interquartile range Median Interquartile range
Testosterone (ng/mL) 1.75 1.33–2.23 1.65 1.45–2.09
DHEAS (ng/mL) 406.8 290.3–495.9 382.7 289.7–468.3
Estradiol (pg/mL) 5,558 3,846–8,837 6,739 4,208–10,380
SHBG (nmol/L) 15.3 13.0–21.2 17.9 12.8–23.2
IGF-1 (ng/mL) 97.9 73.3–130.8† 140.3 83.8–189.1
IGF-2 (ng/mL) 498.6 439.7–551.0† 554.0 495.2–619.1
IGFBP-3 (ng/mL) 1,850 1,532–2,140† 2,129 1,762–2,326
Molar ratios of
   Testosterone/SHBG (×103) 0.37 0.24–0.52 0.32 0.23–0.48
   Estradiol/SHBG 1.42 0.78–2.48 1.67 0.92–2.50
   IGF-1//IGFBP-3 0.20 0.17–0.25 0.21 0.18–0.28
   IGF-2/IGFBP-3 0.94 0.86–1.14 0.99 0.81–1.15
   (IGF-1+IGF-2)/IGFBP-3 1.18 1.04–1.38 1.20 1.05–1.42
†
P<0.05 by Wilcoxon rank sum test
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